Pfizer said close to $14B deal for Medivation – MarketWatch

Pfizer said close to $14B deal for Medivation
MarketWatch
Pfizer Inc. is nearing agreement to buy biotech Medivation Inc. in a move that would add one of the crown jewels of the multibillion-dollar market for cancer drugs to Pfizer's portfolio, according to people familiar with the matter. The $14 billion all …
Pfizer 'In Advanced Talks' to Acquire Medivation for About $14 BillionFortune
Pfizer Reportedly Nears $14 Bln Deal To Acquire MedivationNasdaq
In possible $14 billion ending, Medivation goes back to early daysSan Francisco Business Times (blog)
StreetInsider.com –International Business Times –Wall Street Journal –Bloomberg
all 33 news articles »